Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -18.48% | -23.25% | -34.18% | 1,120.12% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.48% | -23.25% | -34.18% | 1,120.12% | -- |
| Cost of Revenue | 0.27% | -18.67% | -29.43% | 2,536.84% | -- |
| Gross Profit | -39.05% | -31.18% | -40.21% | 366.36% | -- |
| SG&A Expenses | 20.72% | 40.14% | -3.92% | 236.29% | 24.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.80% | 4.40% | -18.98% | 82.80% | 21.99% |
| Operating Income | -1,055.41% | -554.01% | -47.83% | 18.53% | 103.33% |
| Income Before Tax | -416.42% | -380.48% | -203.65% | 14.24% | 92.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -416.42% | -380.48% | -203.65% | 13.64% | 92.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -416.42% | -380.48% | -203.65% | 13.64% | 92.02% |
| EBIT | -1,055.41% | -554.01% | -47.83% | 18.53% | 103.33% |
| EBITDA | -350.22% | -6,325.00% | -53.99% | 27.07% | 113.63% |
| EPS Basic | -375.00% | -340.00% | -188.89% | 13.51% | 91.49% |
| Normalized Basic EPS | -500.00% | -366.67% | -220.00% | 13.04% | 93.10% |
| EPS Diluted | -375.00% | -340.00% | -188.89% | 56.16% | 94.52% |
| Normalized Diluted EPS | -500.00% | -366.67% | -220.00% | 13.04% | 93.10% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |